Biogen Idec/Elan Plan To Appeal Negative CHMP Opinion Of Tysabri For Crohn’s
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee also issues positive opinions on Novartis’ type 2 diabetes therapy Galvus, Pfizer’s oral HIV treatment Celsentri and GSK’s cervical cancer vaccine Cervarix.
You may also be interested in...
Tysabri Clears FDA For Moderate To Severe Crohn’s Disease
Natalizumab will be available for patients with Crohn’s disease by the end of February, Biogen Idec/Elan say.
Tysabri Clears FDA For Moderate To Severe Crohn’s Disease
Natalizumab will be available for patients with Crohn’s disease by the end of February, Biogen Idec/Elan say.
UCB’s Cimzia Rejected For Crohn’s By EMEA Committee
Group also refused to recommend Biogen/Elan’s Tysabri for the disease on appeal.